pridopidine

Phase 3Small molecule

PPrilenia

pridopidine is one of 66 small molecule programs targeting Huntington disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington DiseaseActive, not recruiting

Amyotrophic Lateral SclerosisRecruiting

Huntington DiseasePhase 3

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 3

Recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Robitussin

Ultomiris

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Namenda

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2/3Recruiting

Trial

NCT04297683

Q1 2029

Phase 3Recruiting

Amyotrophic Lateral Sclerosis

NCT07322003

Clinical

Trials by Indication[1]

Huntington's Disease3 trials

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Completed·PPrilenia·Phase 2·NCT02006472·408 enrolled

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Terminated·PPrilenia·Phase 2·NCT02494778·248 enrolled

A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Completed·PPrilenia·Phase 1·NCT03019289·23 enrolled

Amyotrophic Lateral Sclerosis2 trials

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

No longer available·PPrilenia··NCT06069934

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis

Recruiting·PPrilenia·Phase 3·NCT07322003·500 enrolled

Huntington disease2 trials

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

Completed·PPrilenia·Phase 2·NCT01306929·134 enrolled

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Completed·PPrilenia·Phase 3·NCT04556656·499 enrolled

Trial2 trials

HEALEY ALS Platform Trial - Regimen D Pridopidine

Completed·MMerit E. Cudkowicz, MD·Phase 2/3·NCT04615923·163 enrolled

HEALEY ALS Platform Trial - Master Protocol

Recruiting·MMerit E. Cudkowicz, MD·Phase 2/3·NCT04297683·1,500 enrolled

Parkinson's Disease1 trial

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

Terminated·PPrilenia·Phase 2·NCT03922711·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for pridopidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pridopidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pridopidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prilenia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPrilenia

pridopidine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Trials by Indication[1]

Huntington's Disease3 trials

Amyotrophic Lateral Sclerosis2 trials

Huntington disease2 trials

Trial2 trials

Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News